Novo Nordisk is spending $6 billion in Kalundborg, Denmark, to expand the production of active pharmaceutical ingredients (APIs), including peptides used in weight-loss and antidiabetic drugs. The Danish company’s rival, Eli Lilly and Company, recently built a peptide synthesis plant in Kinsale, Ireland.